Ainos, Inc. (AIMD): Nasdaq/NYSE listing notice — Ainos receives Nasdaq deficiency letter for bid price below $1.00

Ainos, Inc.

Deficiency letter received Jan 5, 2023; stock continues trading on Nasdaq Capital Market under AIMD.
Closing bid price below $1.00 for 30 consecutive business days triggered Nasdaq Listing Rule 5550(a)(2).
Company has until July 5, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by July 5, a second 180-day period may be available if other listing standards are met.
Company plans to monitor bid price and consider options to cure, but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ainos, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 5, 2023, Ainos, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its comm

View on SEC.gov

Browse all listing & compliance notices →

Ainos, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-000264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.